OPRK1 and chronic kidney disease: This claim is supported both by the results of studies evaluating the concentration of endogenous opioids in CKD patients and clinical trials evaluating the effectiveness of drugs acting on opioid receptors, such as KOR agonists—difelikefalin, in reducing pruritus [14,31,35,38,43,44].